Bio of Haruhiko Inufusa

Dr. Haruhiko Inufusa was born in 1957 in Okayama, Japan. After graduating from Kindai University Faculty of Medicine in 1982, he joined the Department of Surgery at Kindai University Hospital. While studying at the Kindai University Graduate School, he conducted research on cancer, particularly cancer metastasis. During this time, he established various cancer cell lines and graduated top of the class from the Graduate School in 1988. From 1988 to 1990, he worked mainly on cancer and glycolipids in the laboratory of Professor Sen-ichiro Hakomori at the University of Washington, Seattle, and discovered that the Lewis Y glycolipid in cancer controls blood coagulation and metastasis, and that Lewis X glycolipid associates in cancer metastasis.

In 2001, he was appointed professor at Kindai University Faculty of Medicine (Department of Surgery) and Nara Campus (Department of Clinical Nutrition). As a surgeon, he was one of the first 15 doctors in Japan to perform laparoscopic surgery for colorectal cancer, and his surgical video on laparoscopic surgery techniques has been widely used to train young doctors.

He then worked as a visiting professor at the European Institute of Telesurgery, University of Strasbourg, as a visiting professor in the Department of Surgery, University of Barcelona, and as head of the Advanced Medical and Medical Economics Department, Faculty of Medicine, Kindai University.

In 2003, with the support of the TIMA Establishment, he began research into alcohol metabolism and sugar and lipid metabolism. This research led to the development of the anti-alcohol supplement 'SUPALIV (formulation name: Twendee S)'. Further research with SUPALIV led him to discover its effect in lowering blood sugar levels. This led to new research into antioxidants and the development of 'OXICUT (formulation name: Twendee X)', which activates sugar and lipid metabolism.

In 2013, he established the Division of Anti-Oxidant Research at Gifu University to further his research into antioxidants. As his research progressed, in 2015 he succeeded in developing a mitochondrial supplement called Mtcontrol (formulation name Twendee Mtcontrol) with 1.5 times the antioxidant power of Twendee X.

In 2019, Twendee X was shown to have a preventive effect on dementia in the world's first clinical trial as a dietary supplement in a multi-center, randomized, double-blind, placebo-controlled, prospective intervention study, the most difficult type of clinical trial.

With this opportunity, research into the mechanisms of action of the Twendee range and the prevention and treatment of diseases using these products has continued to bear fruit, with numerous publications and academic presentations. The diseases targeted include cancer, dementia, diabetes, systemic sclerosis (designated as an intractable disease in Japan), infertility, sleep apnea syndrome, radiation damage, hearing loss, dysphagia, allergies, acne and many others.

Since 2010, the manufacture and sale of SUPAILV, Twendee X and Twendee Mtcontrol have been launched sequentially and are now spreading by word of mouth and increasing in sales, making a significant contribution to the prevention and treatment of many patients, due to their high efficacy backed up by tests conducted by third party organizations.

In 2017, he launched the 'Antioxidant Channel' YouTube channel to raise awareness of oxidative stress-related diseases and antioxidant research. The channel now has more than 55,000 followers, thanks to its easy-to-understand explanations of oxidative stress and diseases for the general public and its many opportunities for direct Q&A sessions.

In February 2020, he pointed out that various symptoms of COVID-19 infection, including interstitial pneumonia, are caused by oxidative stress. He immediately started treatment using Twendee X and published the world's first paper proving its efficacy in alleviating the symptoms of patients with Long COVID and COVID-19 vaccine side effects.